OConnell Daniel Joseph 4
4 · Acumen Pharmaceuticals, Inc. · Filed Jan 7, 2026
Insider Transaction Report
Form 4
OConnell Daniel Joseph
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2026-01-05$1.97/sh−4,649$9,163→ 662,839 total - Sale
Common Stock
2026-01-06$1.97/sh−5,102$10,032→ 657,737 total - Sale
Common Stock
2026-01-07$1.99/sh−37,755$74,981→ 619,982 total
Footnotes (4)
- [F1]Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024.
- [F2]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9000 to $2.0600. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9400 to $2.0000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9500 to $2.0300. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.